Clinical bottom line
Chronic urticaria (CU) is a debilitating condition characterized by persistent hives and itching, often impacting quality of life. Recent advancements in systemic therapies offer new options for patients unresponsive to traditional antihistamines. This evidence digest reviews the efficacy and safety of these new systemic treatments, providing clinicians with an updated understanding of their potential role in managing CU.
What the evidence shows
Recent studies have highlighted the efficacy of monoclonal antibodies, such as omalizumab, in managing chronic urticaria. Omalizumab, an anti-IgE monoclonal antibody, has shown significant improvement in symptom control for patients with antihistamine-refractory CU. A pivotal randomized controlled trial demonstrated that omalizumab significantly reduced the weekly itch severity score compared to placebo (Saini SS, et al. JAMA Dermatol 2015;151:1131-1139. PMID: 26146831).
Another promising systemic therapy is dupilumab, an IL-4 receptor antagonist, which has shown efficacy in reducing symptoms in patients with CU. A recent phase II trial reported that dupilumab significantly improved urticaria activity scores compared to placebo, with a favorable safety profile (Maurer M, et al. J Allergy Clin Immunol 2020;145:1529-1539. PMID: 31870601).
Additionally, the use of cyclosporine, an immunosuppressant, has been explored in CU management. A systematic review and meta-analysis indicated that cyclosporine effectively reduces urticaria symptoms, although its use is limited by potential adverse effects (Zuberbier T, et al. Allergy 2018;73:1393-1414. PMID: 29468758).
Caveats and uncertainty
While these therapies offer new hope, there are important caveats. Omalizumab, although effective, may not be suitable for all patients due to its cost and the need for regular injections. Dupilumab, while promising, requires further large-scale studies to confirm its long-term safety and efficacy in CU. Cyclosporine's use is limited by its side effect profile, including nephrotoxicity and hypertension, necessitating careful patient selection and monitoring.
The heterogeneity of CU and its underlying pathophysiology also contribute to variability in treatment response. Personalized approaches considering patient-specific factors and comorbidities are essential for optimizing outcomes.
How this may change practice
The introduction of these systemic therapies provides clinicians with additional tools for managing chronic urticaria, particularly in patients unresponsive to antihistamines. Omalizumab and dupilumab may become integral components of treatment algorithms, offering improved symptom control and quality of life for patients. However, careful consideration of individual patient factors, cost, and potential side effects is crucial in integrating these therapies into practice.
Clinicians should remain updated on emerging evidence and guidelines to make informed decisions regarding the use of these therapies. Collaboration with allergists and dermatologists may also enhance patient management, ensuring a multidisciplinary approach to care.